Use of COVID-19 Vaccines in the United States
Interim Clinical Considerations
Summary of recent changes (last updated October 6, 2023):
- The updated 2023–2024 formulation of Novavax COVID-19 Vaccine is recommended for people ages 12 years and older as follows:
- Initial vaccination: 2 doses of updated (2023–2024 Formula) Novavax COVID-19 Vaccine
- Previously vaccinated with any Original monovalent or bivalent COVID-19 vaccine (Moderna, Novavax, Pfizer-BioNTech, Janssen): 1 dose of updated (2023–2024 Formula) Novavax Vaccine
- People who are moderately or severely immunocompromised may receive 1 or more additional updated (2023–2024 Formula) Novavax vaccine doses.
- People ages 12 years and older have the option of receiving either the updated (2023–2024 Formula) mRNA (Moderna, Pfizer-BioNTech) or updated (2023–2024 Formula) Novavax vaccine.
Reference Materials
- COVID-19 Vaccination Recommendations Infographic (Updated 10/13/2023)
- COVID-19 Vaccination Recommendations Infographic (Immunocompromised) (Updated 10/13/2023)
Get Email Updates
Receive email updates about this page.
Special Situations and Populations